metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P- 76 ELEVATED FIBROSIS LEVEL IN PATIENTS COINFECTED WITH HEPATITIS AND COVID-19...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P- 76 ELEVATED FIBROSIS LEVEL IN PATIENTS COINFECTED WITH HEPATITIS AND COVID-19 DURING A LONGITUDINAL STUDY
Visitas
236
Lucas Lima Da Silva1, Vanessa Duarte Da Costa1, Alanna Calheiros Santos1, Juliana Custódio Miguel1, Luciana Texeira De Barros E Vasconcellos2, Wilian Jeans Wiggers3, Claudia Alexandra Pontes Ivantes3, Priscila Pollo-Flores4, Lia Laura Lewis1, Livia Melo Villar1
1 National Reference Laboratory for Viral Hepatitis, Institute Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil
2 Federal Hospital of State Servers, Ministry of Health, Rio de Janeiro, Brazil
3 Gastroenterology, Hepatology and Liver Transplantation Service, Nossa Senhora das Graças, Paraná, Brazil
4 Federal Fluminense University, Rio de Janeiro, Brazil
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Altered biochemical and hematological markers have been associated with the aggravation of covid-19. There is limited information on the evaluation of the degree of liver injury, especially fibrosis, in infected patients who already have a history of liver injury. This study aimed to evaluate the level of fibrosis in patients coinfected with hepatitis and covid-19 during a one-year follow-up.

Materials and Methods

This is a longitudinal observational study. Two hundred and thirty individuals were recruited for a period of 12 months during the years 2020 to 2021. Blood was collected for hematological and biochemical tests for fibrosis calculation by using APRI index. Nasal and oropharyngeal swab samples were submitted to RT-qPCR test for detection of SARS-CoV-2 RNA.

Results

Mean age of the population was 48 years (± 17.09; 11-90) and half of them were women (115/230). Among the study participants, 40% (90/230) had hepatitis, and of this group, 14% (13/90) had covid-19. Compared to the group without hepatitis (140), 27% (39/140) had only covid-19 and high fibrosis grade (FIB-4) presented as a risk factor for this group. Notably, during the longitudinal study, it was noticed that there was an elevation in the degree of fibrosis among the coinfected patients when compared to the other groups. At the beginning of follow-up and during the acute phase of SARS-CoV-2 infection, coinfected patients presented a low grade of fibrosis (F0); after one year, and in a post-COVID setting, a high grade of fibrosis (F4) was observed in this group. The increase in fibrosis grade was not observed among monoinfected COVID-19 or hepatitis groups.

Conclusions

We observed an increased level of fibrosis among COVID-19 patients with liver disease as a post-covid condition in this group, which may represent an impact of SARS-CoV-2 infection in patients with a history of liver injury.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos